Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) Director Eric Sachetta acquired 27,304 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The stock was purchased at an average cost of $3.54 per share, with a total value of $96,656.16. Following the acquisition, the director directly owned 294,784 shares of the company’s stock, valued at $1,043,535.36. This trade represents a 10.21% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Eric Sachetta also recently made the following trade(s):
- On Friday, August 28th, Eric Sachetta bought 37,537 shares of Sensus Healthcare stock. The shares were purchased at an average cost of $3.44 per share, for a total transaction of $129,127.28.
- On Thursday, August 27th, Eric Sachetta bought 10,925 shares of Sensus Healthcare stock. The stock was purchased at an average price of $3.18 per share, for a total transaction of $34,741.50.
- On Wednesday, August 26th, Eric Sachetta bought 9,708 shares of Sensus Healthcare stock. The stock was purchased at an average price of $3.29 per share, for a total transaction of $31,939.32.
- On Monday, August 24th, Eric Sachetta purchased 34,697 shares of Sensus Healthcare stock. The stock was purchased at an average cost of $3.25 per share, with a total value of $112,765.25.
Sensus Healthcare Price Performance
Shares of NASDAQ SRTS opened at $3.54 on Tuesday. The company has a 50 day simple moving average of $3.07 and a 200-day simple moving average of $3.51. The company has a market capitalization of $58.27 million, a P/E ratio of -3.77 and a beta of 1.10. Sensus Healthcare, Inc. has a 1 year low of $2.66 and a 1 year high of $5.49.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. Greenline Wealth Management LLC purchased a new position in shares of Sensus Healthcare during the fourth quarter worth $513,000. Rothschild Wealth LLC purchased a new stake in shares of Sensus Healthcare in the 4th quarter valued at $500,000. North Star Investment Management Corp. purchased a new stake in shares of Sensus Healthcare in the 1st quarter valued at $500,000. Pacific Ridge Capital Partners LLC lifted its stake in Sensus Healthcare by 21.8% during the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock worth $2,781,000 after acquiring an additional 125,245 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Sensus Healthcare during the 2nd quarter worth about $303,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several brokerages have recently commented on SRTS. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Lake Street Capital cut their price objective on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Weiss Ratings lowered shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Wall Street Zen cut shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Finally, Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Sensus Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $5.83.
Read Our Latest Report on Sensus Healthcare
About Sensus Healthcare
Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.
The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.
See Also
- Five stocks we like better than Sensus Healthcare
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
